×ðÁú¿­Ê±

EN
EN
  • ÓªÒµ×Éѯ

    Öйú£º

    Email: marketing@medicilon.com.cn

    ÓªÒµ×ÉѯרÏߣº400-780-8018

    £¨½öÏÞЧÀÍ×Éѯ£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©

    ´¨É³×ܲ¿µç»°: +86 (21) 5859-1500

    ÍâÑó£º

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

ÔÚÏßÁôÑÔ¡Á
µã»÷Çл»
Customer Center
¿Í»§ÖÐÐÄ

ÖÇÏè½ðÌ©GR1802×¢ÉäÒº¹ýÃôÐÔ±ÇÑ×˳Ӧ֢»ñÅúÁÙ´²

2024-02-02
|
»á¼ûÁ¿£º

΢ÐÅͼƬ_20240129171911.jpg

Ò½ÏßÒ©ÎÅ

1. 2ÔÂ2ÈÕ£¬ÖÇÏè½ð̩ͨ¸æ£¬GR1802×¢ÉäÒº¹ýÃôÐÔ±ÇÑ×˳Ӧ֢»ñµÃÒ©ÎïÁÙ´²ÊÔÑéÅú׼֪ͨÊé¡£

2. 1ÔÂ31ÈÕ£¬CDE¹ÙÍø¹«Ê¾£¬°¢Ë¹Àû¿µ£¨AstraZeneca£©µÝ½»µÄ1ÀàÐÂÒ©baxdrostatƬ»ñµÃÁÙ´²ÊÔÑéĬʾÔÊÐí£¬Ä⿪·¢ÓÃÓÚÖÎÁÆÆäËûÒ©ÎïÖÎÁƺó¿ØÖƲ»¼ÑµÄ¸ßѪѹ»¼Õߣ¬ÒÔ½µµÍѪѹ¡£BaxdrostatÊÇÒ»ÖÖÈ©¹ÌͪºÏ³ÉøÒÖÖÆ¼Á£¨ASI£©¡£

3. 2ÔÂ1ÈÕ£¬°Ù¼ªÉúÎïÐû²¼¸Ã¹«Ë¾Á¢ÒìTILÁÆ·¨BST02×¢ÉäÒº±»ÃÀ¹úFDAÊÚÓè¿ìËÙͨµÀ×ʸñ£¬ÓÃÓÚÖÎÁÆËùÓÐÀàÐ͵ĸΰ©£¨°üÀ¨¸Îϸ°û°©ºÍµ¨¹Ü°©£©¡£Õë¶Ô¸Ã˳Ӧ֢£¬BST02ÒÑÓÚ2023Äê10ÔÂÔÚÃÀ¹ú»ñÅúÁÙ´²¡£

4. 1ÔÂ31ÈÕ£¬ÖÁÉÆÎ¨ÐÂÐû²¼£¬¸Ã¹«Ë¾×ÔÖ÷Ñз¢µÄ·¨²¼Àײ¡»ùÒòÖÎÁƲúÆ·ZS805×¢ÉäÒºÒÑ»ñÖйú¹ú¼ÒÒ©¼à¾ÖÒ©Æ·ÉóÆÀÖÐÐÄ£¨CDE£©ÁÙ´²ÊÔÑéĬʾÔÊÐí£¬¼´½«¿ªÕ¹ÁÙ´²1/2ÆÚÊÔÑé¡£¹ûÕæ×ÊÁÏÏÔʾ£¬ZS805ÊÇÒ»¿îrAAV»ùÒòÖÎÁÆ1ÀàÐÂÒ©¡£

ͶÈÚÒ©ÊÂ

1. ¿ËÈÕ£¬ÔÙÉúÔª£¨Regeneron Pharmaceuticals£©Ðû²¼£¬»ùÓÚÆäÓë2seventy bio¹«Ë¾¸æ¿¢µÄЭÒ齨ÉèRegeneron Cell Medicines£¬²¢ÊÕ¹º2seventy bio¹«Ë¾ÐÂÐÍÃâÒßϸ°ûÁÆ·¨Ñо¿¹ÜÏßµÄËùÓпª·¢ºÍÉÌÒµ»¯È¨Á¦£¬ÒÔ¼°ÆäÒ©Îï·¢Ã÷ºÍÁÙ´²Éú²úÄÜÁ¦¡£

¿Æ¼¼Ò©ÑÐ

1. 2ÔÂ1ÈÕ£¬±±¾©´óѧÁõÌÎÍŶÓÔÚ Nature Chemical Biology ÆÚ¿¯½ÒÏþÁËÌâΪ£ºTracking endogenous proteins based on RNA editing-mediated genetic code expansion µÄÑо¿ÂÛÎÄ¡£¸ÃÑо¿À©Õ¹ÁËÄÚÔ´ÂѰױê¼ÇÒªÁ죬ÌṩÁËÒ»¸öÆÕ±éÊÊÓÃµÄÆ½Ì¨£¬¿ÉÒÔÔÚ»îϸ°ûÖбê¼ÇÄÚÔ´ÂѰ×ÖÊ£¬ÒÔÑо¿Æä¶¨Î»ºÍ¹¦Ð§¡£

[1]Hao, M., Ling, X., Sun, Y. et al. Tracking endogenous proteins based on RNA editing-mediated genetic code expansion. Nat Chem Biol (2024).

Ïà¹ØÐÂÎÅ
È«ÇòÊ׿ÖÇÏè½ðÌ©TSLPË«¿¹É걨ÁÙ´²Ø­¡°ÃÀ¡±ÌìÐÂÒ©ÊÂ
2023-02-15
ÖÇÏè½ðÌ©¿ª·¢µÄÐØÏÙ»ùÖÊÁܰÍÌìÉúËØ£¨TSLP£©Ë«¿¹ÔÚº£ÄÚÉ걨ÁÙ´²¡£ÕâÊÇÈ«ÇòÊ׿îÉ걨ÁÙ´²µÄTSLPË«¿¹£¬Ò²ÊǵÚ11¿îÉ걨ÁÙ´²µÄTSLP°ÐÏòÒ©Îï¡£
Ò»ÈÕ 2 ¸ö£¡ºãÈðÒ½Ò©ºÍÖÇÏè½ðÌ©IL-17Aµ¥¿¹ÔÚÖйú»ñÅú
2024-08-27
8ÔÂ27ÈÕ£¬NMPA ¹ÙÍøÏÔʾ£¬ºãÈðÒ½Ò© IL-17A µ¥¿¹·òÄÇÆæÖéµ¥¿¹µÄÉÏÊÐÉêÇ루CXSS2300026£©ÒÑ»ñµÃÅú×¼£¬ÓÃÓÚÖÎÁƳÉÈËÖÐÖØ¶È°ß¿éÐÍÒøÐ¼²¡¡£ÕâÊÇÒ»¿îÔÚº£ÄÚ»ñÅúµÄ¹ú²ú IL-17A µ¥¿¹¡£8ÔÂ27ÈÕ£¬ÖÇÏè½ðÌ©Ðû²¼£¬NMPAÒÑÅú×¼¸Ã¹«Ë¾1ÀàÐÂÒ©ÈüÁ¢Ææµ¥¿¹×¢ÉäÒºÉÏÊУ¬ÓÃÓÚÖС¢ÖضȰ߿é×´ÒøÐ¼²¡µÄÖÎÁÆ¡£ÈüÁ¢Ææµ¥¿¹ÊÇÒ»¿î¿¹IL-17Aµ¥¿Ë¡¿¹Ìå×¢ÉäÒº¡£
7.12ÒÚÃÀÔª£ºÖÇÏè½ðÌ©BCMA/CD3Ë«¿¹ÊÚȨ¸øCullinan Therapeutics | 1·ÖÖÓÒ©ÎÅËÙÀÀ
2025-06-05
6ÔÂ4ÈÕ£¬Cullinan TherapeuticsÐû²¼ÓëÖÇÏè½ðÌ©£¨Genrix Bio£©¸æ¿¢ÏàÖú£¬»ñµÃBCMAxCD3Ë«ÌØÒìÐÔTϸ°ûÏνӿ¹ÌåvelinotamigÔÚÈ«Çò£¨´óÖлªÇø³ýÍ⣩ȫ˳Ӧ֢µÄ¶À¼ÒÊÚȨ¡£Æ¾Ö¤Ð­Ò飬Cullinan½«ÏòÖÇÏè½ð̩֧¸¶2000ÍòÃÀÔªÊ׸¶¿î£¬»ñµÃ´óÖлªÇøÒÔÍâÈ«ÇòËùÓм²²¡ÁìÓòµÄ¶À¼Ò¿ª·¢ºÍÉÌÒµ»¯È¨Ò档δÀ´ÖÇÏè½ðÌ©ÉÐÓÐ×ʸñ»ñµÃ×î¸ß2.92ÒÚÃÀÔªµÄ¿ª·¢ºÍî¿ÏµÀï³Ì±®¸¶¿î£¬ÒÔ¼°ÌØÊâ×î¸ß4ÒÚÃÀÔªµÄÏúÊÛÀï³Ì±®¸¶¿î¡£
¡Á
ËÑË÷ÑéÖ¤
µã»÷Çл»
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿